Critical Path Institute’s (C-Path) flagship event returned to downtown Washington, D.C. this September 15-16 at the Washington Marriott at Metro Center.
Critical Path Institute’s Global Impact Conference (CGIC) convened a global community of regulators, industry leaders, scientists, clinicians, those with lived experience and advocates committed to accelerating the development of better treatments for people worldwide.
In 2026, CGIC once again served as a working forum designed not just for dialogue, but for action. Across three days of plenary sessions, targeted workshops, and collaborative dialogues, participants aligned on practical solutions to advance drug development across rare diseases, neurology, pediatrics, and beyond.
This exclusive event brought together leaders across the ecosystem to help redefine the evidence-generation enterprise for drug development in the 21st century. Sessions explored innovations t transform the paradigm for the entire evidence generation enterprise for new medical products. Additional discussions focused on integrating novel methodologies, expanding the use of real-world data to inform regulatory decision-making, and ensuring that patient experiences remain central to every stage of development.
Each day was anchored by keynote discussions that defined priorities and framed working sessions that translated insights into clear, near-term commitments, ensuring that progress extends well beyond the conference itself.
CGIC is uniquely positioned at the intersection of collaboration and regulatory science. By bringing together diverse stakeholders with a shared purpose, the conference catalyzes alignment on the tools, data, and frameworks needed to move therapies forward, faster and more effectively.
At its core, CGIC reflected C-Path’s mission: to lead collaborations that accelerate drug development and improve outcomes for patients. For the individuals and families waiting for new treatments, the urgency is clear, and CGIC is where meaningful progress began.
Recap Materials
Event Conclusion Press Release
